Enliven Therapeutics (ELVN) EBIT Growth (3y) (2022 - 2026)

Enliven Therapeutics (ELVN) EBIT Growth (3y) (2022 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Growth (3y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 16.96%
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 38.78%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 13.47%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -12.10%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 69.02%
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Enliven Therapeutics 3.22 Bn 3.22 Bn - -19.22%

Historic Data

Download Data
DateValue
Mar 31, 2026 -19.22%
Dec 31, 2025 -49.98%
Sep 30, 2025 -31.91%
Jun 30, 2025 -46.90%
Mar 31, 2025 -54.00%
Dec 31, 2024 -23.34%
Sep 30, 2024 -25.61%
Jun 30, 2024 -23.16%
Mar 31, 2024 -36.22%
Dec 31, 2023 -25.31%
Sep 30, 2023 -24.74%
Jun 30, 2023 -25.03%
Mar 31, 2023 -30.71%
Dec 31, 2022 -10.74%
Sep 30, 2022 -16.69%
Jun 30, 2022 -17.51%
Mar 31, 2022 -27.43%